Tcr2 Therapeutics Inc

NASDAQ:TCRR   10:05:49 AM EDT
5.24
+0.13 (+2.54%)
Earnings Announcements

Tcr² Therapeutics Reports Third Quarter 2021 Financial Results

Published: 11/10/2021 12:01 GMT
Tcr2 Therapeutics Inc (TCRR) - Tcr² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update.
Expect Cash on Hand to Support Operations Through 2023.
Plans to File an Ind for Tc-510, First Enhanced Truc-t Cell, in Q1 of 2022.
Qtrly Loss per Share $0.69.
To Select a Lead Candidate for Its Allogeneic Program in 2022.
Q3 Earnings per Share View $-0.65 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.71

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.72

More details on our Analysts Page.